Neurocarrus Inc Profile last edited on: 11/9/2021
CAGE: 7KVS4
UEI: Y3QSXZCMGMV6
Business Identifier: Addressing the way pain is treated 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 20
County: Monterey
Congr. District: 20
County: Monterey
Public Profile
Using cell engineering and microbiology to find solutions to long standing medical and patient needs to include pain treatment, cancer and vaccines, Neurocarrus is a biotech company current strucctured around developmen of a novel drug delivery technology safely to disrupt pain signals without addiction-forming medications or disruption of muscular control. Designated N-001, the firm describe what they have as a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 2 | NIH | $3,021,555 | |
| Project Title: Selective Actin Remodeling of Sensory Neurons for Acute Pain Management | ||||
Key People / Management
Paul Blum -- Co-Founder and CEO
Marina Blum -- Manager Operations
Samerender Nagam Hanumantharao -- Research Scientist
Marina Blum -- Manager Operations
Samerender Nagam Hanumantharao -- Research Scientist
Company News
There are no news available.
